Hjem › Diffust stort B-celle lymfom › Florida
Diffust stort B-celle lymfom kliniske forsøg i Florida
23 studier for Diffust stort B-celle lymfom søger deltagere på steder i Florida.
Byer i Florida
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Miami Cancer Institute at Baptist Health, Inc., Miami
- Advent Health Cancer Institute, Orlando
- Orlando Health Cancer Institute, Orlando
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Mayo Clinic in Florida, Jacksonville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06834373A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Clermont Oncology Center ( Site 0182), Clermont
- Bioresearch Partner ( Site 0157), Hialeah
- Orlando Health Cancer Institute ( Site 0169), Ocoee
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Mayo Clinic Jacksonville, Jacksonville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06091865A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton
- Clermont Oncology Center ( Site 0174), Clermont
- BRP-Hialeah Hospital ( Site 0182), Hialeah
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130), Boca Raton
- Baptist MD Anderson Cancer Center ( Site 0176), Jacksonville
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0140), Miami Beach
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- University of Miami - Sylvester Cancer Center, Miami
- Florida Cancer Specialists - Sarasota, Sarasota
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
- Moffitt Cancer Center, Tampa
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT05757219Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- North Florida/ South Georgia VA Medical Center, Gainesville
- Mount Sinai Comprehensive Cancer Center, Miami
- Orlando Health Cancer Institute, Orlando
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06806033Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Florida, Jacksonville
- AdventHealth, Orlando
- Moffitt Cancer Center, Tampa
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Mayo Clinic, Jacksonville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07424833DALY II USA/ MB-CART2019.1 for DLBCL
- Baptist Health Miami Cancer Institute, Miami
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Moffitt Cancer Center, Tampa
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. jul. 2026 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- University of Miami Sylvester Cancer Center, Miami
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 5. mar. 2026 · NCT05800366B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT06191887Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- UF Health Cancer Institute - Gainesville, Gainesville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. feb. 2026 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Holy Cross Hospital, Fort Lauderdale
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. okt. 2025 · NCT05890352A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.